David A. Siegel Biocryst Pharmaceuticals Inc Transaction History

Two Sigma Advisers, LP

$42.5 Billion
Q1 2024

A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Biocryst Pharmaceuticals Inc stock. As of the latest transaction made, Two Sigma Advisers, LP holds 2,473,412 shares of BCRX stock, worth $15.3 Million. This represents 0.03% of its overall portfolio holdings.

Number of Shares

2,473,412

Previous 2,268,012 9.06%

Holding current value

$15.3 Million

Previous $13.6 Million 7.52%

% of portfolio

0.03%

Previous 0.03%

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$4.89 - $7.65 $1 Million - $1.57 Million	205,400 Added 9.06%	2,473,412 $12.6 Million
Q4 2023 Feb 14, 2024	SELL	$4.98 - $6.77 $502,482 - $683,093	-100,900 Reduced 4.26%	2,268,012 $13.6 Million
Q3 2023 Nov 14, 2023	BUY	$6.71 - $7.92 $1.55 Million - $1.83 Million	231,300 Added 10.82%	2,368,912 $16.8 Million
Q2 2023 Aug 14, 2023	SELL	$6.96 - $8.81 $453,096 - $573,531	-65,100 Reduced 2.96%	2,137,612 $15 Million
Q1 2023 May 15, 2023	BUY	$7.94 - $11.84 $1.84 Million - $2.74 Million	231,800 Added 11.76%	2,202,712 $18.4 Million

Q4 2022 Feb 14, 2023	SELL	$10.5 - $14.2 $471,450 - $637,580	-44,900 Reduced 2.23%	1,970,912 $22.6 Million
Q3 2022 Nov 14, 2022	SELL	$10.79 - $14.81 $729,404 - $1 Million	-67,600 Reduced 3.24%	2,015,812 $25.4 Million
Q2 2022 Aug 15, 2022	BUY	$7.89 - $17.88 $2.46 Million - $5.59 Million	312,400 Added 17.64%	2,083,412 $22 Million
Q1 2022 May 16, 2022	SELL	$11.56 - $19.76 $4.4 Million - $7.53 Million	-380,900 Reduced 17.7%	1,771,012 $28.8 Million
Q4 2021 Feb 14, 2022	BUY	$11.18 - $15.46 $2.58 Million - $3.57 Million	230,900 Added 12.02%	2,151,912 $29.8 Million
Q3 2021 Nov 15, 2021	BUY	$14.21 - $17.65 $17.2 Million - $21.4 Million	1,212,900 Added 171.29%	1,921,012 $27.6 Million
Q2 2021 Aug 16, 2021	BUY	$9.5 - $17.24 $4.6 Million - $8.34 Million	483,900 Added 215.82%	708,112 $11.2 Million
Q1 2021 May 17, 2021	SELL	$7.37 - $13.61 $8 Million - $14.8 Million	-1,085,500 Reduced 82.88%	224,212 $2.28 Million
Q4 2020 Feb 16, 2021	SELL	$3.37 - $8.61 $1.95 Million - $4.99 Million	-579,600 Reduced 30.68%	1,309,712 $9.76 Million
Q3 2020 Nov 16, 2020	SELL	$3.43 - $5.53 $787,185 - $1.27 Million	-229,500 Reduced 10.83%	1,889,312 $6.49 Million
Q2 2020 Aug 14, 2020	BUY	$1.9 - $5.61 $985,910 - $2.91 Million	518,900 Added 32.43%	2,118,812 $10.1 Million
Q1 2020 May 15, 2020	BUY	$1.6 - $4.11 $156,960 - $403,191	98,100 Added 6.53%	1,599,912 $3.2 Million
Q4 2019 Feb 14, 2020	BUY	$1.59 - $3.45 $996,771 - $2.16 Million	626,900 Added 71.65%	1,501,812 $5.18 Million
Q3 2019 Nov 14, 2019	BUY	$2.5 - $3.73 $1.09 Million - $1.62 Million	435,300 Added 99.02%	874,912 $2.51 Million
Q2 2019 Aug 14, 2019	BUY	$2.91 - $9.15 $715,278 - $2.25 Million	245,800 Added 126.82%	439,612 $1.67 Million
Q1 2019 May 15, 2019	BUY	$7.38 - $9.72 $209,592 - $276,048	28,400 Added 17.17%	193,812 $1.58 Million
Q4 2018 Feb 14, 2019	SELL	$6.51 - $9.6 $213,528 - $314,880	-32,800 Reduced 16.55%	165,412 $1.34 Million
Q3 2018 Nov 14, 2018	BUY	$5.52 - $7.99 $160,080 - $231,710	29,000 Added 17.14%	198,212 $1.51 Million
Q2 2018 Aug 14, 2018	BUY	$4.6 - $6.52 $346,895 - $491,686	75,412 Added 80.4%	169,212 $970,000
Q1 2018 May 15, 2018	SELL	$4.35 - $5.82 $2,610 - $3,492	-600 Reduced 0.64%	93,800 $447,000
Q4 2017 Feb 14, 2018	BUY	$4.16 - $5.33 $37,024 - $47,437	8,900 Added 10.41%	94,400 $464,000
Q3 2017 Nov 14, 2017	BUY	$4.1 - $5.97 $350,549 - $510,435	85,500	85,500 $448,000

Others Institutions Holding BCRX

# of Institutions

258

Shares Held

182M

Call Options Held

839K

Put Options Held

816K

View Full List

About BIOCRYST PHARMACEUTICALS INC

Ticker BCRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,944,992
Market Cap $1.15B
Description
BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat...

More about BCRX

Track David A. Siegel's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.

Account